anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Therapeutic preparations of living animal cells are prepared from the organs of foctal or sexually immature mammals by subjecting them to mechanical disintegration followed by digestion with ferments such as trypsin which removes connective tissue from the cells which remain living and unaltered.  The organ is disintegrated in contact with a liquid medium, for example, Hanks solution, trypsin (about 0.25%) is added and digestion allowed to continue at 37 DEG  C. until as much connective tissue as possible is digested whilst the cells remain living (about 5 to 10 minutes). Filtration gives a filtrate which is a suspension of cells in digestive fluid and a non-filterable portion which can be re-treated.  Further digestion in the filtrate is prevented by cooling in ice water and the filtrate is then centrifuged to give a deposit of cells which is washed free from digestive fluid and preferably also from necrotoxins.  The cells may then be introduced into ampoules, freeze dried until the moisture content is about 1 to 3% and stored or alternatively the cells may be suspended in physiological salt or Ringer&#39;s solution for injection. Differing species of cells from the same organ, having been freed from connective tissue may be separated for example by filtration or centrifugation.  Examples of organs from which preparations may be made according to the process include thyroid, pancreas, liver, spleen, hypophysis, ovary, the bulls&#39; testicles. Specification 716,161 is referred to.
The currently recommended therapeutic drug monitoring of voriconazole has improved the efficacy of this treatment and reduced its adverse effects, especially for treatment and prophylaxis of invasive aspergillosis. However, dose adjustments made as part of this therapeutic drug monitoring only occur at the earliest 3 to 5 days after the initiation of treatment, whereas it is essential to achieve effective concentrations from the start of treatment. Simple a priori dose adjustment approaches based on CYP2C19 genotype have been shown to improve voriconazole exposure and treatment response. However other factors such as the patient\&#39;s inflammatory status or age also influence voriconazole exposure, suggesting that strategies for individualizing initial voriconazole doses could be improved by integrating all covariates influencing voriconazole pharmacokinetics. In this line, a previous multicenter and international study has developped and validated an algorithm for calculating the first maintenance doses integrating not only the CYP2C19 genotype, but also the inflammatory status, the patient\&#39;s age, and the presence (or not) of hematological malignancy. Here, the investigators propose to evaluate the interest of this multiparametric algorithm for improving initial exposure (within the first 4 days) to voriconazole in patients suffering from haematological malignancies.
A jaundice analysis system includes a database and a processing device for accessing the database. The processing device includes: a data processing module for generating a training data according to an image data, correlating the training data with a category data, and storing the training data in the database; and a deep learning module for training a target convolutional neural network module with the training data correlating with the category data to obtain a trained convolutional neural network module. The image data includes a first sclera image. The trained convolutional neural network module of the processing device generates a testing data according to an input image data. The input image data includes a second sclera image of a target subject. The testing data indicates the target subject&#39;s bilirubin concentration range.
NEW MATERIAL:A 1,4-dihydro-4-oxo-3-quinolinecarboxylic acid derivative shown by the formula I (R&lt;1&gt; is H, or ethyl group; R&lt;2&gt; is alkyl; Y is O, or S). EXAMPLE:8-n-Propoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid ethyl ester. USE:Useful for preventing and remedying allergic diseases caused by an antigen- antibody reaction, such as asthma, dermatitis, rhinitis, conjunctivitis, etc. Has low toxicity. PREPARATION:As shown the equation, a 2-substituted aniline derivative shown by the formula II is reacted with ethoxymethylmalonic acid diethyl ester in the absence of a solvent under heating at 100-150 deg.C to give a (2-substituted anilinomethylene)malonic acid diethyl ester derivative shown by the formula III. Then, the compound shown by the formula III is reacted in a high-boiling solvent at 250 deg.C, to give a compound shown by the formula Ia. Then it is further hydrolyzed with an alkali conventionally, to give a compound shown by the formula Ib.
An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5&#34; retroviral LTR nucleic acid sequence, a 3&#34; retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5&#34; LTR or the 3&#34; LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5&#34; LTR and the 3&#34; LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5&#34; and a 3&#34; retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4. A method for transforming a cell is also provided using a virus or a vector of the invention, as is a method for introducing a transgene into a cell that is not able to produce viral particles with a single viral vector. A method is also provided for preventing or treating disorder in a subject using the adenoviral vectors of the invention. A pharmaceutical composition is also provided that includes an adenoviral vector of the invention and a pharmaceutically acceptable carrier.
PURPOSE:To perform economical elimination of pyrogen in higher efficiency in quick and safe manner, by filtering prourokinase through a semipermeable membrane followed by contact of the resulting filtrate with an adsorbent for pyrogen elimination. CONSTITUTION:Firstly, an aqueous solution of purified prourokinase (PUK) (e.g., E. coli-producing gene recombinant PUK with a specific activity &gt;=140,000 unit/mg) containing several thousands - ten thousands ng/ml of endotoxin of several W/V% protein concentration is dissolved in a buffer solution with a pH of ca.5 containing ca.10wt.% of ethanol to prepare a PUK sample solution (A). Secondly, the solution A is filtered through a ultrafilter membrane such as of polystyrene base with a fractional molecular weight of ca.300,000 under such conditions as 11.5-27cm&lt;2&gt; of filtering area based on 50-200ml of the solution A and 2.0-4.5kg/cm&lt;2&gt; of filtering pressure to produce a filtrate (B). Thirdly, a nitrogen-contg. heterocyclic compound (e.g., histamine) is conjugated with a water-insoluble carrier (e.g., cellulose) to prepare an adsorbent for pyrogen adsorption (C). Finally, the solution B is admixed with the adsorbent C in the volume ratio 1:1-1,000 followed by centrifuging or the like, thus recovering a prourokinase solution with the pyrogen eliminated.
The subject invention concerns materials and methods for treating and/or preventing diseases associated with accumulation of Aβ peptide in neural tissue. The subject invention also concerns materials and methods for treating and/or preventing stress disorders, such as post-traumatic stress disorder (PTSD). In one embodiment, a method of the invention comprises administering a therapeutically effective amount of cotinine, or a pharmaceutically acceptable salt thereof, to a person or animal in need of treatment. The methods of the invention can be used to prevent and/or treat Alzheimer&#39;s disease, Parkinson&#39;s disease, and/or Down&#39;s syndrome. The subject invention also concerns compositions that comprise cotinine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or adjuvant.The subject invention concerns materials and methods for detecting and diagnosing conditions associated with accumulation of Aβ peptide in neural tissue, such as Alzheimer&#39;s disease and Parkinson&#39;s disease, using the chemical cotinine. In one embodiment, the method comprises administering cotinine labeled with a detectable label to a person or animal. The presence of labeled cotinine in neural tissue is then determined. The level and/or location of cotinine can be analyzed and a diagnosis made. The subject invention also concerns cotinine labeled with a detectable label. In one embodiment, the cotinine is labeled with a radioisotope that can be detected by Positron Emission Tomography (PET) or single photon emission computed tomography (SPECT).
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a dye composition containing a class 2 hair bleaching agent which bleaches the hair to the 7th stage and at the same time dyes it into one of various color tones in one step.  &lt;P&gt;SOLUTION: This dye is a derivative stable against the bleaching agent for an azo, triaryl methane, thiazine, or nitro dye. Its inactivating or weakly activating chemical group increases the stability of a dye in an alkaline bleaching agent, if it is on the aromatic ring of the dye or if it is bonded to ortho and/or para position in regard to the center of a bonded chromophore or an auxochrome. A dye molecule is liable to be attacked by the bleaching agent and finally decomposed if it lacks an inactive substituent or a weak active substituent at the ortho and/or para position or has a strong active group at the position. The inactivating and protective chemical group may be a nitro, halogen, cyano, carboxy, sulfone, alkyl or aromatic group, and must not be an amino, hydroxy, alkoxy, or alkylamide group.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an oily hair-coloring agent in which a specific amount of organic polymer powder is formulated with a pigment.  &lt;P&gt;SOLUTION: The oily hair-coloring agent is obtained by formulating an oily hair-coloring agent with a pigment and a specific amount of organic polymer powder. The content of the organic polymer powder is preferably 5-40 wt.%, further preferably 10-25 wt.%. An acrylic or silicon-based powder is preferably used as the type of the organic polymer powder. In the oily hair-coloring agent, degree in change of hardness of the oily hair-coloring agent by change of air temperature is small and as a result, the amount of the oily hair-coloring agent is always uniformly taken out when actually used and the hair coloring agent enables natural finish of the colored hair.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PURPOSE: To obtain the composition containing a triterpenoid compound or its salt and a carrier for external agents, excellent in the antiphlogistic action, excellent in supply stability and productivity, and useful as an antiphlogistic action. CONSTITUTION: This composition contains a compound of the formula [R&lt;1&gt; is OH (protected with a lower alkyl group); R&lt;2&gt; is hydroxymethyl, lower alkoxymethyl; R&lt;3&gt; is (protected)carboxyl] or its salt and a carrier for external agents. The compound of the formula is obtained, e.g. by extracting the roots of Paeonia albiflora with supercritical or high pressure state carbon dioxide, developing the extract containing the compound of the formula in an adsorption column chromatograph. and subsequently developing the adsorption column supercritical or high pressure state carbon dioxide containing ethanol in different concentrations to separate and purify the compound. The objective composition is administered at a dose of 1.0-5.0mg/kg body once for an adult and at a dose of &lt;=5.0mg/kg body a day for an adult as the compound of the formula.
NEW MATERIAL:An esterification product of a carboxy-modified silicone with an alcohol expressed by formula I or II (R1 to R3 are alcohol residue; (n) is an integer of &gt;=0). EXAMPLE:An esterification product of a carboxy-modified silicone [with about 1000 average molecular weight and about 10 polymerization degree (n)]. USE:With excellent characteristics such as slipperiness, water repellency and glass unique to silicone oils and excellent in compatibility with other ingredients without any stickiness even at a high viscosity. PREPARATION:A compound expressed by formula III and an alcohol corresponding to R1 to R3 are subjected to esterification reaction according to a conventional method to afford the objective compound expressed by formula I or II. Furthermore, the aforementioned compound has effects as follows. The compound is colorless and odorless and capable of freely changing various physical properties such as lubricity, viscosity or compatibility and has excellent compatible touch with the skin with emulsifiability, humectant properties and emollience and high safety, etc., without irritating the skin.
FIELD: medicine, proctology, pharmacy. SUBSTANCE: invention relates to method for making suppository &#34;Apiprost&#34; recommended for complex therapy in inflammatory processes in rectum intestine, prostatitis, hemorrhoid, for treatment of anal fissures. Proposed suppository contains homogenate or lyophilizate of drone breeding, mother milk, bee breed, natural honey, propolis, pot-marigold tincture, bee wax, anhydrous lanoline, solid fat or vitepsol or butyrum-cacao. Invention provides the complete release of active substances, shows the expressed curative effect and minimal risk for development of adverse effects. EFFECT: enhanced effectiveness and valuable medicinal properties of suppository. 3 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an oily cosmetic which gives a soft touch, when coated, can uniformly be spread, does not make the unevenness of skins and lips prominent, forms cosmetic films controlling oil gloss and having naturally beautiful appearances, prevents dryness, and is excellent in emollient effect.  &lt;P&gt;SOLUTION: This oily cosmetic is characterized by comprising (A) a fructooligosaccharide fatty acid ester having a saccharide-average polymerization degree of 10 to 60 and a fatty acid esterification degree per monosaccharide unit of ≥2.2, (B) a long chain alkyl group-containing partially cross-linked organopolysiloxane, and (C) a liquid oil except silicone oils. Further, a solid oil may be contained. The liquid oil (C) except the silicone oils is preferably a liquid oil containing at least one or more ester bonds in the molecule, or especially preferably an ester oil which is liquid at the ordinary temperature, has hydroxy groups in the molecule and has a mol.wt. of 300 to 1,000.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To exhibit long-term anti-thrombotic property besides simplicity and versatility by containing at least an ionic complex of at least specific several kinds of mucopolysaccharides and the like and fourth class phosphonium and an inorganic antibacterial agent as an essential component. SOLUTION: An anti-thrombotic composition with antibacterial property given is formed by containing fat soluble mucopolysaccharide and the like composed of an ionic complex of at least a single kind of mucopolysaccharide and the like and fourth class phosphonium and an inorganic antibacterial agent as an essential component. As the mucopolysaccharide and the like, heparin or heparin metallic salt has particularly excellent anti-thrombogenic capacity. The fourth class phosphonium has a structure of a formula (R&lt;1&gt; , R&lt;2&gt; and R&lt;3&gt; show an alkyl group having the carbon number of 1 to 12 or an aryl group having the carbon number of 6 to 12 or an aralkyl group having the carbon number of 7 to 20, and R&lt;4&gt; shows an alkyl group having the carbon number of 1 to 25). In this, only a single kind may be used, or several kinds may be used at the same time.  For example, an antibacterial agent and antibacterial glass or the like using metal such as silver, copper and zinc as an effective component, can be used as the inorganic antibacterial agent.
The disclosure pertains to a secure intelligent networked system for identifying and correcting a defect in a health care service and method for using the same. The system receives data regarding patient care, generally obtained from commercial insurance claims, customer claims or Medicare claims. The system operates on a plurality of nodes configured based on a set of metrics associated with the appropriateness of health care measures. The system may generate a determination regarding the appropriateness of the measure. The system may further produce a second determination denoting a physician&#39;s overall conformity with appropriate standards of practice. Finally, the system may generate a knowledge narrative indicating an appropriate action.
1433417 Antibiotic A-2315 ELI LILLY &amp; CO 30 July 1973 [31 July 1972] 36111/73 Headings C2A and C2C The new antibiotic &#34;A-2315&#34; having the possible structural formula is prepared by aerobic cultivation of the organism Actinoplanes philippinensis NRRL 5462 (nov. spec.). It may be separated from the fermentation medium by conventional procedures, e.g. extraction with chloroform and purification by chromatography on silica gel. The antibiotic is stated to have antibacterial activity, in particular against gram-positive streptococci, especially those responsible for periodontal disease. It also has animal growth promoting activity and may be used to combat plant fungal infections as well as a general disinfectant.
The invention discloses a traditional Chinese medicinal preparation for treating gonarthromeningitis. The traditional Chinese medicinal preparation is characterized in that selected Chinese herbal raw materials comprise respectively, by weight, 15 parts of vegetable sponge of luffa, 15 parts of ligustrum lucidum, 15 parts of Herba Siegesbeckiae, 30 parts of radix scrophulariae, 9 parts of cyathula root, 24 parts of menispermaceae, 30 parts of Job&#39;s tears, 30 parts of Smilax glabra, 10 parts of cassia twig, 20 parts of Chinese angelica, 3 parts of Asarum Herb, 30 parts of Radix Astragali, 12 parts of bighead atractylodes rhizome, 10 parts of safflower and 12 parts of rhizoma alismatis. The selected raw medicinal materials have complementary drug properties and effects. Mutual inhibition, mutual restraint and mutual-detoxication among medicines in compatibility are avoided. Mutual reinforcement and mutual-assistance among the medicines are remarkable. The traditional Chinese medicinal preparation has an effect of enhancing immunity, has efficacy of expelling wind and removing cold, activating blood circulation to dissipate blood stasis and relieving swelling and pain, and is an orally-taken preparation which is prepared from pure Chinese herbal medicines and is used for treating gonarthromeningitis.
PURPOSE: A nucleic acid aptamer which specifically HER-2-overexpressing breast cancer cells or tissues is provided to enhance survival rate of breast cancer patients. CONSTITUTION: A nucleic acid aptamer of 15-60nts contains one nucleic acid of sequence numbers 9, 12, 13, and 17 and specifically binds to HER-2-overexpressing breast cancer cells or tissues. The nucleic acid aptamer includes chemical modification. The chemical modification is substitution of a hydroxyl group at ribose 2&#39; site of a nucleotide into hydrogen atoms, fluorine, -O-alkyl group, -O-acyl group, or amino group. The nucleic acid aptamer is used for detecting breast cancer. A method for detecting breast cancer comprises a step of contacting the nucleic acid aptamer with breast tissue, breast cells, blood, serum, plasma, sputum, and urine.
-261 5 Medical devices may be utilized for local and regional therapeutic agent delivery. These therapeutic agents or compounds may reduce a biological organism&#39;s reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the prevention of thrombosis. The drugs, agents, and/or 10 compounds may also be utilized to treat specific disorders, including restenosis, vulnerable plaque, and atherosclerosis in type 2 diabetic patients. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Various materials and coating methodologies may be utilized to maintain the agents or compounds on the medical device until 15 delivered and positioned. 26/03/09,va 17860 speci,261 5014 5040 5054 5028 5014 5040FIG. 4O 7000 5028 FIG. 41 5014 5040 FIG. 43 7000
We disclose a telemedicine device for tracking, dispensing, and retrieving medical supplies as well as methods of its use. The device includes a medical supply dispensing and retrieving station which includes a medical supply dispenser and medical supply receptacle. Both the medical supply dispenser and medical supply receptacle may include multiple compartments which house medical supplies. The device may include a communication port for receiving prescription information. The device includes a personal identification indicator which verifies the identity of the user and links the identity to the user&#39;s prescription information. The device may include medical devices. The medical devices may conduct measurements to confirm efficacy of a medical supply or screen for side effects. The device may confirm proper usage of a medical supply by weighing an unused portion of the medical supply and comparing it to the weight expected for the amount that should be remaining.
The present invention describes an injectable calcium polyphosphate (CPP) gel with dense structure, which can be applied as injectable bone void filler in medical field, such as orthopedic and dental applications. Amorphous CPP powder with fine particle size (&lt;75 pm) can be completely dissolved in water, forming a homogeneous gelation phase separated from water phase. This homogeneous CPP gel with disentangled inorganic polyphosphate chains shows viscoelasticity and superior adhesion to natural bone, metal implant surfaces and other ceramic material surfaces. The CPP gel is biomimetic and biodegradable with strong osteoconductivity and osteoinductivity. The manufacturing procedure is easy and reproducible. The mechanical strength of CPP gel is controllable by modifications, such as sintering, incorporation of other biomaterials, etc.
PURPOSE:To obtain a preventing and treating agent having high preventing and treating effects on Salmonella infectious disease and free from problem of resistance to the medicine and environmental pollution, low in toxicity to animal and hardly remaining in animal bodies and having high safety. CONSTITUTION:This preventing and treating agent for Salmonella infectious disease of animal contains at least one inactivated bacterial strain of Salmonella belonging to O4 group and at least one inactivated bacterial strain of Salmonella belonging to O9 group on classification of Salmonella by O antigen. As Salmonella belonging to O4 group, Salmonella typhimurium, Salmonella paratyphi-B, etc., and as Salmonella belonging to O9 group, Salmonella enteritidis, Salmonella dublin, Salmonella typhi are exemplified and, as the combination thereof, S. typhimurium/S. dublin and S. typhimurium/S. enteritides are preferably used and these Salmonella bacteria have especially large effects on prevention and treatment of cow Salmonella infectious diseases. When this preventing and treating agent is orally administered continuously for &gt;=5 days, further good result is obtained.